Want to see AU:BIO full AI Analyst Report?
BIO Stock Chart & Stats
AU$0.40
-AU$0.01(-1.89%)
At close: 4:00 PM EST
AU$0.40
-AU$0.01(-1.89%)
Day’s Range― - ―
52-Week RangeAU$0.20 - AU$0.63
Previous CloseN/A
Volume242.26K
Average Volume (3M)278.69K
Market Cap
AU$59.28M
Enterprise ValueAU$64.05M
Total Cash (Recent Filing)AU$3.36M
Total Debt (Recent Filing)AU$2.43M
Price to Earnings (P/E)58.7
Beta1.21
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding227,998,030
10 Day Avg. Volume235,222
30 Day Avg. Volume278,692
Financial Highlights & Ratios
PEG Ratio-4.04
Price to Book (P/B)21.27
Price to Sales (P/S)5.40
P/FCF Ratio-34.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.75Price Target Upside87.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)AU$36.50M
Bulls Say, Bears Say
Bulls Say
Top-line GrowthConsistent revenue growth at 16.14% signals durable demand for the company’s probiotic products and supports continued investment in distribution and practitioner adoption. Sustained top-line growth underpins long-term scale economics and capacity to fund R&D and marketing.
High Gross MarginsA 61.12% gross margin provides structural room to absorb SG&A and channel costs while maintaining product profitability. High product-level margins support pricing flexibility, margin resilience against input cost swings, and capacity to invest in product development and commercialization.
Manageable LeverageModerate leverage (D/E 0.66) and a positive ROE indicate a balanced capital structure that preserves financial flexibility. This reduces solvency risk, enables selective borrowing for growth initiatives, and supports multi-year investment without excessive refinancing pressure.
Bears Say
Cash Conversion RiskNegative operating cash flow despite reported profit highlights weak conversion of earnings into cash. This structural cash-generation gap forces reliance on external financing or working-capital measures, limiting the firm’s ability to self-fund growth or weather revenue volatility.
Thin Net ProfitabilityA net margin of ~1.2% leaves minimal earnings buffer after operating costs and taxes. Persistently thin profitability constrains retained earnings for reinvestment, reduces shock absorption to cost inflation, and makes the business sensitive to modest revenue or margin deterioration.
Low Operating MarginsLow EBIT/EBITDA margins point to limited operational efficiency and weak conversion of gross profits into operating cash. Structural margin pressure restricts reinvestment capacity, hampers scalability across channels, and leaves less room to compete on marketing or pricing over time.
Biome Australia Ltd News
BIO FAQ
What was Biome Australia Ltd’s price range in the past 12 months?
Biome Australia Ltd lowest share price was AU$0.20 and its highest was AU$0.63 in the past 12 months.
What is Biome Australia Ltd’s market cap?
Biome Australia Ltd’s market cap is AU$59.28M.
When is Biome Australia Ltd’s upcoming earnings report date?
Biome Australia Ltd’s upcoming earnings report date is Sep 01, 2026 which is in 48 days.
How were Biome Australia Ltd’s earnings last quarter?
Biome Australia Ltd released its earnings results on Feb 22, 2026. The company reported AU$0.005 earnings per share for the quarter, missing the consensus estimate of AU$0.006 by -AU$0.001.
Is Biome Australia Ltd overvalued?
According to Wall Street analysts Biome Australia Ltd’s price is currently Undervalued.
Does Biome Australia Ltd pay dividends?
Biome Australia Ltd does not currently pay dividends.
What is Biome Australia Ltd’s EPS estimate?
Biome Australia Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biome Australia Ltd have?
Biome Australia Ltd has 227,998,030 shares outstanding.
What happened to Biome Australia Ltd’s price movement after its last earnings report?
Biome Australia Ltd reported an EPS of AU$0.005 in its last earnings report, missing expectations of AU$0.006. Following the earnings report the stock price went down -4.587%.
Which hedge fund is a major shareholder of Biome Australia Ltd?
Currently, no hedge funds are holding shares in AU:BIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biome Australia Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.75 (87.50% Upside)
AU$0.75 (87.50% Upside)
Blogger Sentiment
Bullish
AU:BIO Sentiment 100%
Sector Average 62%
Sector Average 62%
Insider Transactions
Bought Shares
Worth AU$146.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.96%
12-Months-Change
Fundamentals
Return on Equity
17.85%
Trailing 12-Months
Asset Growth
17.94%
Trailing 12-Months
Company Description
Biome Australia Ltd
Biome Australia Limited, founded in 2018 and headquartered in Cremorne, Australia, specializes in the development, commercialization, and global distribution of live biotherapeutic and complementary health products. The company's product line features live biotherapeutics under the Activated Probiotics brand, organic nutritional supplements branded as Activated Nutrients, and athletic performance and recovery items named Activated X Performance. These offerings are accessible to consumers through both community pharmacies and independent health practitioners.
BIO Stock 12 Month Forecast
Average Price Target
AU$0.75
▲(87.50% Upside)
Technical Analysis
Immuron Limited
―
Avecho Biotechnology Limited
―
Anatara Lifesciences Ltd
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―